Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05969704
Other study ID # TRUS prostatic biopsy
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date June 1, 2024

Study information

Verified date May 2024
Source Menoufia University
Contact Ahmed M Mehanna
Phone 201026906035
Email ahmedmehana1994@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to compare the accuracy of Magnetic resonance imaging targeted (fusion) versus cognitive prostatic biopsy in biopsy-naïve suspected cancer prostate patient


Description:

Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide, counting 1,276,106 new cases and causing 358,989 deaths (3.8% of all deaths caused by cancer in men. The clinical prostate cancer detection rate of TRUS-guided needle biopsies is only 25-30%. while more than 50% of cancers that require definitive treatment remain undetected during initial biopsies . Clinical studies have shown that 75-80% of non-palpable carcinomas remain undetected during initial prostate biopsies. Multi-parametric prostate MRI has a high sensitivity for the detection of prostate adenocarcinoma and has shown promise for targeted biopsy of lesions that may be missed on routine systematic trans -rectal ultrasound (TRUS) biopsy . The most recent European Association of Urology guidelines recommend MRI before prostate biopsy for biopsy-naïve men with elevated PSA, the strength rating of the recommendation is weak. A systematic 12-core trans-rectal ultrasound-guided systematic biopsy (TRUS-SB) is still carried out for biopsy-naïve men at present. However, the TRUS-SB technique has several limitations, including over-diagnosis of clinically insignificant prostate cancer (CISCa), under-diagnosis of clinically significant prostate cancer (CSCa), false negative biopsy results and biopsy-related complications, such as bleeding and infections . Targeted prostate biopsies from MRI-suspicious lesions have been shown to improve the cancer detection rate (CDR) of CSCa compared with systematic TRUS-guided biopsies . Currently, three biopsy techniques are used for TB from MRI-suspicious lesions: in-bore MRI biopsies, cognitive magnetic resonance imaging trans-rectal ultrasound fusion targeted biopsy (COG-TB) and software guided magnetic resonance imaging-ultrasound fusion targeted biopsies (MRUS-TB). Inbore MRI biopsies that are carried out with an MRI-compatible guidance device can target suspicious lesions accurately; however, such biopsies are time-consuming and expensive . In the COG-TB technique, a physician samples a location that has been visually estimated using ultrasound and is considered to correspond to the location of a suspicious lesion that was detected on MRI. However, when the suspicious lesion is completely invisible (isoechoic or too small) on TRUS, the accuracy of such biopsies is likely reduced . The accuracy of COG-TB might be influenced by multiple factors, including the alignment of prostate landmarks, the physician's experience and so on. for these reasons, MRUS-TB where software fuses the MRI images with real-time TRUS images to guide the operator to biopsy the suspicious lesions is more commonly carried out; however, the optimal TB method remains unclear.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - prostate biopsy-naïve men - PSA levels of up to 20 ng/mL - Multi-parametric prostate MRI revealed a PIRAD 4 or PIRAD 5. Exclusion Criteria: - PSA level greater than 20 ng/mL - patient with history of TRUS biopsy - patient diagnosed as cancer prostate or with distant metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
MRI fusion targeted prostatic biopsy
combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
MRI cognitive targeted prostatic biopsy
the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion

Locations

Country Name City State
Egypt Menoufia University Hospital Shibin Al Kawm Menoufia

Sponsors (1)

Lead Sponsor Collaborator
Menoufia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary detection of clinically significant prostate cancer accuracy of MRI targeted fusion versus cognitive prostatic biopsy in biopsy-naïve suspected cancer prostate patient to detect clinically significant prostate cancer two weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01086956 - Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy N/A
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02687308 - Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique N/A
Completed NCT01284608 - Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) N/A
Completed NCT04421781 - Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
Recruiting NCT05740956 - A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Not yet recruiting NCT05851521 - To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES) N/A
Completed NCT01998685 - Prothrombotic Factors and Anaesthesia in Prostate Cancer N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Not yet recruiting NCT06439784 - Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy N/A
Terminated NCT03606889 - Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia N/A
Completed NCT03481816 - Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Phase 1
Completed NCT01171729 - Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer Phase 1/Phase 2
Recruiting NCT05623878 - 68Ga-labeled NY108 PET Imaging in Patients Early Phase 1
Not yet recruiting NCT05184790 - LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Completed NCT02564120 - North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)